Laura Deming is an early-stage venture capitalist who exclusively invests in the longevity sector. See sector focus and contact routes.
Laura Deming is an early-stage venture capitalist who exclusively invests in the longevity sector, targeting Seed through Series B companies developing therapeutics for age-related diseases with check sizes up to $1 million[2][12]. Her distinctive thesis treats aging itself as a disease rather than an inevitable biological consequence, focusing on extending healthy human lifespan through drugs, gene editing, and cellular reprogramming[1][2]. Notable portfolio companies include Unity Biotechnology, which developed senolytic drugs for aging diseases, as well as Precision BioSciences, Navitor Pharmaceuticals, and Metacrine[1][5].
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in San Francisco when building a target list.
Investors like Laura Deming · Full investor directory · Investor access · Company funding database